Harninkontinenz bei geriatrischen Patienten: Medikamentöse Therapie

Zusammenfassung

Einleitung 1/2019 wurde ein update der seit 2005 in AWMF eingestellten und fortlaufend aktualisierten Leitlinie „Harninkontinenz bei geriatrischen Patienten – Diagnostik und Therapie“ durch die interdisziplinäre Arbeitsgruppe „Harninkontinenz“ der Deutschen Gesellschaft für Geriatrie (DGG) publiziert. Aus dieser Leitlinie, die als offizielle Leitlinie DGG akkreditiert ist, stellt der vorliegende Artikel das Kapitel „Medikamentöse Therapie“ dar.

Methodik In einem strukturierten Bewertungsprozess identifizierte eine Literaturrecherche zunächst die vorhandene Literatur im Kontext des „geriatrischen Patienten“, wie er als zumeist über 70jährig und multimorbid oder über 80jährig durch die Fachgesellschaften definiert ist. Primäre Berücksichtigung fanden randomisierte, doppelblinde, plazebokontrollierte Studien sowie bereits vorhandene Leitlinien zum Thema. Wo keine solchen Untersuchungen vorlagen oder aus methodischen Gründen prinzipiell nicht durchführbar sind, wurden auch Publikationen anderen Designs (nicht randomisierte Untersuchungen, Fallkontrollstudien) zur Leitlinienerstellung herangezogen. Die daraus resultierenden Leitlinienempfehlungen wurden in einem strukturierten Abstimmungsprozess unterzogen; das Ergebnis ist in Prozent der zustimmenden Gruppenmitgliedern angegeben.

Ergebnisse Die medikamentöse Therapie der Überaktiven Blase, der Belastungsharninkontinenz und der Überlaufinkontinenz sowie die unspezifische medikamentöse Therapie mit Antidiuretika wurde vor dem besonderen Hintergrund des vulnerablen, potentiell kognitiv eingeschränkten und im Rahmen der Multimorbidität und Multimedikation durch Medikamenteninteraktionen besonders gefährdeten Patienten betrachtet. Dabei fand das relevante Nebenwirkungsprofil der eingesetzten Substanzen besondere Berücksichtigung.

Schlussfolgerungen Eine medikamentöse Therapie der Harninkontinenz bedarf bei den besonders vulnerablen, häufig multimedizierten Patienten eine besonders sorgfältige Indikationsstellung und Überwachung in Kenntnis des spezifischen Risiko- und Nebenwirkungsprofils der eingesetzten Substanzen.

Abstract

Introduction 1/2019 we presented an update of the AWMF guideline ‘urinary incontinence in frail elderly – diagnostics and therapy’. Since its introduction in 2015 the guideline has been under a continuous revision process by the working group ‘Incontinence’ of the German Society for Geriatrics (DGG). From this guideline which is accredited as an official guideline of the DGG we present here the chapter about pharmacological therapy.

Methods A profound literature search was done in a structured evaluation process in the context of a ‘frail elderly’. Most medical societies define a ‘frail elderly’ as someone older than 70 years and multimorbide or older than 80y. We focused on randomized, double blind, placebo controlled studies as well as already published guidelines in this field. In the case no studies were available or not feasible other publications such as not randomized studies or case reports were taken into consideration for our guideline. Recommendations resulted from a structured voting process and the results are stated as percentage of members who agreed.

Results Pharmacological therapy of OAB, stress incontinence and overflow incontinence as well as unspecific treatment with antidiuretics was evaluated with special focus on vulnerable, potentially cognitively impaired frail elderly. We took a closer look on special side effect profile of the above mentioned drugs with regard to the individual multimorbidity and multimedication.

Conclusion Pharmacological therapy of urinary incontinence in frail elderly needs strict indication. Knowledge about drug metabolization and substance interactions as well as close monitoring of possible side effects are indispensable in this vulnerable group of patients.

Schlüsselwörter

Antimuskarinika - Mirabegron - Botulinum Toxin - Duloxetin - Cholinesterasehemmer

Keywords

Antimuscarinics - Mirabegron - Botulinum Toxin - Duloxetin - Cholinesterase inhibitors

• Literatur

• 1 Abrams P, Cardozo L, Fall M. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003; 61: 37-49
• 2 Mansfield KJ, Chandran JJ, Vaux KJ. et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J Pharmacol Exp Ther 2009; 328: 893-899
• 3 Mansfield KJ, Liu L, Mitchelson FJ. et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 2005; 144: 1089-1099
• 4 Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent) 2007; 20: 307-214
• 5 Manjunatha R, Pundarikaksha HP, Hanumantharaju BK. et al. A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder. J Clin Diagn Res 2015; 9: FC05-9
• 6 Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 1993; 150: 1657-1667
• 7 Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45: 420-429
• 8 Zinner N, Susset J, Gittelman M. et al. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Int J Clin Pract 2006; 60: 119-126
• 9 Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol 2005; 23: 248-252
• 10 Hill S, Khullar V, Wyndaele JJ. et al. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 239-247
• 11 Sand PK, Morrow JD, Bavendam T. et al. Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 827-835
• 12 Kaplan SA, Roehrborn CG, Gong J. et al. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. BJU Int 2012; 109: 1831-1840
• 13 Staskin D, Khullar V, Michel MC. et al. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 2011; 30: 1480-1485
• 14 Kaplan SA, Schneider T, Foote JE. et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int 2011; 107: 1432-1440
• 15 van Kerrebroeck PE, Heesakkers J, Berriman S. et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. Int J Clin Pract 2010; 64: 584-593
• 16 Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986; 135: 966-968
• 17 Holmes DM, Montz FJ, Stanton SL. Oxybutinin versus propantheline in the management of detrusor instability. A patient-regulated variable dose trial. Br J Obstet Gynaecol 1989; 96: 607-612
• 18 Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Br J Urol 1980; 52: 472-475
• 19 Tapp AJ, Cardozo LD, Versi E. et al. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br J Obstet Gynaecol 1990; 97: 521-526
• 20 Thompson IM, Lauvetz R. Oxybutynin in bladder spasm, neurogenic bladder, and enuresis. Urology 1976; 8: 452-454
• 21 Thuroff JW, Bunke B, Ebner A. et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-816
• 22 Zorzitto ML, Holliday PJ, Jewett MA. et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989; 18: 195-200
• 23 Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 52: 409-417
• 24 Appell RA, Sand P, Dmochowski R. et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001; 76: 358-363
• 25 Barkin J, Corcos J, Radomski S. et al. A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin Ther 2004; 26: 1026-1036
• 26 MacDiarmid SA, Anderson RU, Armstrong RB. et al. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol 2005; 174: 1301-1305
• 27 Corcos J, Casey R, Patrick A. et al. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. BJU Int 2006; 97: 520-527
• 28 Anderson RU, MacDiarmid S, Kell S. et al. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 2006; 17: 502-511
• 29 Sand P, Zinner N, Newman D. et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007; 99: 836-844
• 30 Dmochowski RR, Nitti V, Staskin D. et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005; 23: 263-270
• 31 Dmochowski RR, Davila GW, Zinner NR. et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002; 168: 580-586
• 32 Mazur D, Gocking K, Wehnert J. et al. [Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence. A multicenter study for optimizing dosage]. Urologe A 1994; 33: 447-452
• 33 Voigt R, Halaska M, Voigt P. et al. [Experience with the conservative treatment of incontinence using the anticholinergic agent propiverin (Mictonorm)]. Cesk Gynekol 1988; 53: 180-184
• 34 Wehnert J, Sage S. [Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle]. Z Urol Nephrol 1989; 82: 259-263
• 35 Dorschner W, Stolzenburg JU, Griebenow R. et al. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol 2000; 37: 702-708
• 36 Junemann KP, Halaska M, Rittstein T. et al. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 2005; 48: 478-482
• 37 Junemann KP, Hessdorfer E, Unamba-Oparah I. et al. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int 2006; 77: 334-339
• 38 Abrams P, Cardozo L, Chapple C. et al. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol 2006; 13: 692-698
• 39 Lee KS, Lee HW, Choo MS. et al. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’. BJU Int 2010; 105: 1565-15670
• 40 Cardozo L, Lisec M, Millard R. et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919-1924
• 41 Cardozo L, Hessdorfer E, Milani R. et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008; 102: 1120-1127
• 42 Metello J, Nogueira B, Torgal M. et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 1021-1025
• 43 Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. BJU Int 2006; 97: 1256-1261
• 44 Chapple CR, Martinez-Garcia R, Selvaggi L. et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48: 464-470
• 45 Chapple CR, Rechberger T, Al-Shukri S. et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93: 303-310
• 46 Oreskovic S, But I, Banovic M. et al. The efficacy and safety of solifenacin in patients with overactive bladder syndrome. Coll Antropol 2012; 36: 243-248
• 47 Herschorn S, Heesakkers J, Castro-Diaz D. et al. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms. Curr Med Res Opin 2008; 24: 3513-3521
• 48 Ho CH, Chang TC, Lin HH. et al. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 2010; 109: 702-708
• 49 Karram MM, Toglia MR, Serels SR. et al. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009; 73: 14-18
• 50 Nilvebrant L, Hallen B, Larsson G. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997; 60: 1129-1136
• 51 Stahl MM, Ekstrom B, Sparf B. et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995; 14: 647-655
• 52 Drutz HP, Appell RA, Gleason D. et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 283-289
• 53 Jonas U, Hofner K, Madersbacher H. et al. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol 1997; 15: 144-151
• 54 Homma Y, Paick JS, Lee JG. et al. Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int 2003; 92: 741-747
• 55 van Kerrebroeck PE, Kelleher CJ, Coyne KS. et al. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. Health Qual Life Outcomes 2009; 7: 13
• 56 Kaplan SA, Roehrborn CG, Dmochowski R. et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 328-332
• 57 Madersbacher H, Stohrer M, Richter R. et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995; 75: 452-456
• 58 Stohrer M, Bauer P, Giannetti BM. et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 1991; 47: 138-143
• 59 Madersbacher H, Stohrer M, Richter R. et al. [High-dose trospium chloride in therapy of detrusor hyperreflexia]. Urologe A 1991; 30: 260-263
• 60 Cardozo L, Chapple CR, Toozs-Hobson P. et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000; 85: 659-664
• 61 Zinner N, Gittelman M, Harris R. et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171: 2311-2315 , quiz.
• 62 Rudy D, Cline K, Harris R. et al. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006; 67: 275-280
• 63 Dmochowski RR, Sand PK, Zinner NR. et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology 2008; 71: 449-454
• 64 Sand PK, Dmochowski RR, Zinner NR. et al. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20: 1431-1438
• 65 Zinner NR, Dmochowski RR, Staskin DR. et al. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn 2011; 30: 1214-1219
• 66 Nabi G, Cody JD, Ellis G. et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; CD003781
• 67 Lee YS, Choo MS, Lee JY. et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract 2011; 65: 997-1004
• 68 Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931-937
• 69 Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int 2010; 105: 1268-1275
• 70 Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001; 185: 56-61
• 71 Herschorn S, Pommerville P, Stothers L. et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (≤ 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin 2011; 27: 375-382
• 72 Meek PD, Evang SD, Tadrous M. et al. Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci 2011; 56: 7-18
• 73 Halaska M, Ralph G, Wiedemann A. et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003; 20: 392-399
• 74 Callegari E, Malhotra B, Bungay PJ. et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72: 235-246
• 75 Oelke M, Becher K, Castro-Diaz D. et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 2015; 44: 745-755
• 76 Pietzko A, Dimpfel W, Schwantes U. et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-343
• 77 Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-644
• 78 Diefenbach K, Arold G, Wollny A. et al. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years. BJU Int 2005; 95: 346-349
• 79 Diefenbach K, Donath F, Maurer A. et al. Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig 2003; 23: 395-404
• 80 Hughes KM, Lang JC, Lazare R. et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992; 22: 859-869
• 81 Kay G, Crook T, Rekeda L. et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-326
• 82 Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005; 173: 493-498
• 83 Staskin D, Kay G, Tannenbaum C. et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc 2010; 58: 1618-1619
• 84 Staskin DR, Harnett MD. Effect of trospium chloride on somnolence and sleepiness in patients with overactive bladder. Curr Urol Rep 2004; 5: 423-426
• 85 Wagg A, Dale M, Tretter R. et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013; 64: 74-81
• 86 Wagg A, Khullar V, Michel MC. et al. Long-term safety, tolerability and efficacy of flexible-dose fesoterodine in elderly patients with overactive bladder: open-label extension of the SOFIA trial. Neurourol Urodyn 2014; 33: 106-114
• 87 Wagg A, Khullar V, Marschall-Kehrel D. et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc 2013; 61: 185-193
• 88 Ouslander JG, Schnelle JF, Uman G. et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995; 43: 610-617
• 89 Goode PS, Burgio KL, Locher JL. et al. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc 2002; 50: 808-816
• 90 van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis 1979; 1: 701-719 Originally published as „Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus“. Zeitschrift fur Hygiene und Infektionskrankheiten 26: 1-56, 1897
• 91 Duchen LW. Motor nerve growth induced by botulinum toxin as a regenerative phenomenon. Proc R Soc Med 1972; 65: 196-197
• 92 Chancellor MB, Fowler CJ, Apostolidis A. et al. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 2008; 5: 319-328
• 93 Giannantoni A, Di Stasi SM, Nardicchi V. et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 2006; 175: 2341-2344
• 94 Lucioni A, Bales GT, Lotan TL. et al. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008; 101: 366-370
• 95 Schulte-Baukloh H, Weiss C, Stolze T. et al. Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 2005; 66: 82-87
• 96 Antunes AA, Srougi M, Coelho RF. et al. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Nat Clin Pract Urol 2007; 4: 155-160
• 97 Maria G, Brisinda G, Civello IM. et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 259-264
• 98 Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management. J Urol 2006; 175: S5-10
• 99 Schurch B, Hauri D, Largo M. et al. [Effects of Botulinum A Toxin on the periurethral striated sphincter of the neurogenic bladder. Preliminary study]. J Urol (Paris) 1990; 96: 375-380
• 100 Smith CP, Radziszewski P, Borkowski A. et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 2004; 64: 871-875
• 101 Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol 2006; 50: 806-809
• 102 Cohen BL, Barboglio P, Rodriguez D. et al. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009; 28: 205-208
• 103 Karsenty G, Baverstock R, Carlson K. et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract 2014; 68: 731-742
• 104 Duthie J, Wilson DI, Herbison GP. et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007; CD005493
• 105 Sahai A, Khan MS, Le Gall N. et al. Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008; 71: 455-459
• 106 Karsenty G, Elzayat E, Delapparent T. et al. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007; 177: 1011-1014
• 107 Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007; 178: 1359-1363
• 108 Safari S, Jamali S, Habibollahi P. et al. Intravesical injections of botulinum toxin type A for management of neuropathic bladder: a comparison of two methods. Urology 2010; 76: 225-230
• 109 Frohme C, Varga Z, Olbert P. et al. [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis]. Urologe A 2010; 49: 639-644
• 110 Gaillet S, Bardot P, Bernuz B. et al. Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity. Prog Urol 2012; 22: 1064-1070
• 111 Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 2007; 26: 531-536
• 112 Krhut J, Kopecky J. [Intra-detrusor injection of botulinumtoxin in patients with refractory overactive bladder]. Ceska Gynekol 2007; 72: 402-406
• 113 Krivoborodov GG, Vasil'ev AV, Shumilo DV. et al. [Botulinum toxin type A in patients with overactive bladder]. Urologiia 2010; 36-40
• 114 Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004; 63: 868-872
• 115 Kuschel S, Werner M, Schmid DM. et al. Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 905-909
• 116 Neugart F, Groh R, Gotz T. et al. [Injections of botulinum toxin a into the detrusor vesicae for treatment of refractory detrusor hyperactivity in non-neurological patients]. Aktuelle Urol 2006; 37: 212-217
• 117 Petrou SP, Parker AS, Crook JE. et al. Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc 2009; 84: 702-706
• 118 Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007; 177: 2231-2236
• 119 Schmid DM, Sauermann P, Werner M. et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006; 176: 177-185
• 120 Werner M, Schmid DM, Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 2005; 192: 1735-1740
• 121 Mohee A, Khan A, Harris N. et al. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2012; 111: 106-113
• 122 Rovner E, Kennelly M, Schulte-Baukloh H. et al. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011; 30: 556-562
• 123 Fowler CJ, Auerbach S, Ginsberg D. et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 2012; 62: 148-157
• 124 Sahai A, Dowson C, Khan MS. et al. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009; 103: 1509-1515
• 125 Cohen BL, Caruso DJ, Kanagarajah P. et al. Predictors of response to intradetrusor botulinum toxin-A injections in patients with idiopathic overactive bladder. Adv Urol 2009;
• 126 White WM, Pickens RB, Doggweiler R. et al. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol 2008; 180: 2522-2526
• 127 Jeffery S, Fynes M, Lee F. et al. Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007; 100: 1302-1306
• 128 Dowson C, Watkins J, Khan MS. et al. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012; 61: 834-839
• 129 Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010; 58: 919-926
• 130 Miotla P, Cartwright R, Skorupska K. et al. Urinary retention in female OAB after intravesical Botox injection: who is really at risk?. Int Urogynecol J 2017; 28: 845-850
• 131 Chapple C, Khullar V, Nitti VW. et al. Efficacy of the beta3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. Eur Urol 2014; 67: 11-14
• 132 Chapple CR, Kaplan SA, Mitcheson D. et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296-305
• 133 Herschorn S, Barkin J, Castro-Diaz D. et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 2013; 82: 313-320
• 134 Nitti VW, Chapple CR, Walters C. et al. Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. Int J Clin Pract 2014; 68: 972-985
• 135 Wagg A, Cardozo L, Nitti VW. et al. The efficacy and tolerability of the beta3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Age Ageing 2014; 43: 666-675
• 136 Sussman D, Yehoshua A, Kowalski J. et al. Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis. Int J Clin Pract 2017;
• 137 Alcantara-Montero A. Combined treatment of solifenacin and mirabegron, an alternative in patients with overactive bladder (BESIDE study). Actas Urol Esp 2016; 40: 593-594
• 138 Abrams P, Kelleher C, Staskin D. et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol 2017; 35: 827-838
• 139 Abrams P, Kelleher C, Staskin D. et al. Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). Eur Urol 2015; 67: 577-588
• 140 Lee J, Moy S, Meijer J. et al. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig 2013; 33: 429-440
• 141 Groen-Wijnberg M, van Dijk J, Krauwinkel W. et al. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Pharmacokinet 2017; 42: 417-429
• 142 Krauwinkel W, van Dijk J, Schaddelee M. et al. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 2012; 34: 2144-2160
• 143 Gibson W, MacDiarmid S, Huang M. et al. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus 2017; 3: 629-638
• 144 Norton PA, Zinner NR, Yalcin I. et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187: 40-48
• 145 Dmochowski RR, Miklos JR, Norton PA. et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003; 170: 1259-1263
• 146 van Kerrebroeck P, Abrams P, Lange R. et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004; 111: 249-257
• 147 Cardozo L, Drutz HP, Baygani SK. et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstet Gynecol 2004; 104: 511-519
• 148 Ghoniem GM, Van Leeuwen JS, Elser DM. et al. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 2005; 173: 1647-1653
• 149 Robinson D, Abrams P, Cardozo L. et al. The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Eur J Obstet Gynecol Reprod Biol 2011; 159: 457-460
• 150 Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005; 95: 354-357
• 151 Agrawal MS, Yadav A, Yadav H. et al. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol 2009; 25: 474-478
• 152 Bhomi KK, Bhattachan CL. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia. Nepal Med Coll J 2011; 13: 178-181
• 153 Kim HL, Kim JC, Benson DA. et al. Results of treatment with tamsulosin in men with acute urinary retention. Tech Urol 2001; 7: 256-260
• 154 Rasner PI, Pushkar D. [Administration of two uroselective alpha-adrenoblockers in pharmacological treatment of acute urinary retention in patients with prostatic adenoma]. Urologiia 2009; 30-34
• 155 Zeif HJ, Subramonian K. Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. Cochrane Database Syst Rev 2009; CD006744
• 156 Chapple CR. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996; 29: 129-144
• 157 The Italian Alfuzosin Cooperative Group. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. Eur Urol 1995; 27: 128-134
• 158 Buzelin JM, Hebert M, Blondin P. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. Br J Urol 1993; 72: 922-927
• 159 Jardin A, Bensadoun H, Delauche-Cavallier MC. et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Br J Urol 1993; 72: 615-620
• 160 Jardin A, Bensadoun H, Delauche-Cavallier MC. et al. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. Br J Urol 1994; 74: 579-584
• 161 Lukacs B, McCarthy C, Grange JC. Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice. Eur Urol 1993; 24 (Suppl. 01) 34-40
• 162 Martelli A, Pacifico P, Casadei G. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group. Eur Urol 1993; 24 (Suppl. 01) 28-33
• 163 Martorana G, Giberti C, Di Silverio F. et al. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. Eur Urol 1997; 32: 47-53
• 164 Schulman CC, De Sy W, Vandendris M. et al. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Acta Urol Belg 1994; 62: 15-21
• 165 Bendix Holme J, Christensen MM, Rasmussen PC. et al. 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. Scand J Urol Nephrol 1994; 28: 77-82
• 166 Chapple CR, Carter P, Christmas TJ. et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-56
• 167 Christensen MM, Bendix Holme J, Rasmussen PC. et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scand J Urol Nephrol 1993; 27: 39-44
• 168 Fawzy A, Braun K, Lewis GP. et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109
• 169 Gillenwater JY, Conn RL, Chrysant SG. et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115
• 170 Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995; 76: 325-336
• 171 Chapple CR, Wyndaele JJ, Nordling J. et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 155-167
• 172 Dong Z, Wang Z, Yang K. et al. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med 2009; 55: 129-136
• 173 Lee HS, Kim SW, Oh SJ. et al. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study. Korean J Urol 2012; 53: 178-183
• 174 Masumori N, Tsukamoto T, Horita H. et al. alpha1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol 2013; 20: 421-428
• 175 Oelke M, Giuliano F, Mirone V. et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61: 917-925
• 176 Ren RM, Kou M, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis. Chin Med J (Engl) 2010; 123: 234-238
• 177 Schulman CC, Cortvriend J, Jonas U. et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 145-154
• 178 Karadag E, Oner S, Budak YU. et al. Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. Int Urol Nephrol 2011; 43: 949-954
• 179 Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 1993; 2: 929-935
• 180 Elhilali MM, Ramsey EW, Barkin J. et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: 335-342
• 181 Lepor H, Machi G. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate 1992; 20: 89-95
• 182 Lepor H, Williford WO, Barry MJ. et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335: 533-539
• 183 Roehrborn CG, Oesterling JE, Auerbach S. et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47: 159-168
• 184 Chapple CR, Montorsi F, Tammela TL. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 2011; 59: 342-352
• 185 Martin DJ, Lluel P, Guillot E. et al. Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther 1997; 282: 228-235
• 186 Novara G, Tubaro A, Sanseverino R. et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol 2013; 31: 997-1008
• 187 Watanabe T, Ozono S, Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res 2011; 39: 129-142
• 188 Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008; 62: 1547-1559
• 189 Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. Curr Opin Ophthalmol 2009; 20: 37-41
• 190 Chang DF, Braga-Mele R, Mamalis N. et al. ASCRS White Paper: clinical review of intraoperative floppy-iris syndrome. J Cataract Refract Surg 2008; 34: 2153-2162
• 191 Tufan HA, Gencer B, Kara S. et al. Alterations in iris structure and pupil size related to alpha-1 adrenergic receptor antagonists use: implications for floppy iris syndrome. J Ocul Pharmacol Ther 2013; 29: 410-413
• 192 Cantrell MA, Bream-Rouwenhorst HR, Steffensmeier A. et al. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists. Ann Pharmacother 2008; 42: 558-563
• 193 Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol 2008; 15: 981-985
• 194 Costantini E, Lazzeri M, Bini V. et al. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int 2009; 83: 311-315
• 195 Kakizaki H, Ameda K, Kobayashi S. et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol 2003; 10: 576-581
• 196 Lee KS, Han DH, Lee YS. et al. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. J Korean Med Sci 2010; 25: 117-122
• 197 Meyer LE, Brown JN. Tamsulosin for voiding dysfunction in women. Int Urol Nephrol 2012; 44: 1649-1656
• 198 Pischedda A, Pirozzi FarinaF, Madonia M. et al. Use of alpha1-blockers in female functional bladder neck obstruction. Urol Int 2005; 74: 256-261
• 199 Stankovich E, Borisov VV, Demina TL. [Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis]. Urologiia 2004; 48-51
• 200 Robinson D, Cardozo L, Terpstra G. et al. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 2007; 100: 840-845
• 201 Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 1985; 134: 443-449
• 202 Barendrecht MM, Oelke M, Laguna MP. et al. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based?. BJU Int 2007; 99: 749-752
• 203 Steendam CM, Vincent HH, Kastelijn EA. [Neurological complications caused by desmopressin in adults with nocturia]. Ned Tijdschr Geneeskd 2011; 155: A3273
• 204 Sand PK, Dmochowski RR, Reddy J. et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 2013; 190: 958-964
• 205 Weiss JP, Herschorn S, Albei CD. et al. Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol 2013; 190: 965-972
• 206 Johnson 2nd TM, Miller M, Tang T. et al. Oral ddAVP for nighttime urinary incontinence in characterized nursing home residents: a pilot study. J Am Med Dir Assoc 2006; 7: 6-11